Insight Molecular Diagnostics (IMDX) Preferred Stock Liabilities (2022 - 2024)

Insight Molecular Diagnostics (IMDX) has 3 years of Preferred Stock Liabilities data on file, last reported at $5.3 million in Q1 2024.

• Quarterly Preferred Stock Liabilities fell 3.62% year-over-year to $5.3 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $5.3 million (down 3.62% YoY) and the FY2023 annual result came in at $5.1 million, down 3.32% from the prior year.
• Preferred Stock Liabilities advanced to $5.3 million in Q1 2024 per IMDX's latest filing, from $5.1 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $5.5 million in Q1 2023, with the low at $4.7 million in Q2 2023.
• Average Preferred Stock Liabilities over 3 years is $5.1 million, with a median of $5.1 million recorded in 2022.
• Year-over-year, Preferred Stock Liabilities retreated 2.66% in 2023 and retreated 3.62% in 2024.
• Insight Molecular Diagnostics' Preferred Stock Liabilities stood at $5.3 million in 2022, then retreated by 3.32% to $5.1 million in 2023, then rose by 4.02% to $5.3 million in 2024.
• Business Quant data shows IMDX's Preferred Stock Liabilities at $5.3 million in Q1 2024, $5.1 million in Q4 2023, and $4.9 million in Q3 2023.